Integration of CSF proteogenomics in the diagnosis and management of diffuse gliomas
Objective
Study Objectives: Prospective validation of Cerebral Spinal Fluid (CSF) diagnostic signatures that distinguish diffuse gliomas (DGs) from other intra-axial lesions identified on imaging. Validation of CSF-based proteomic signatures in GBM to resolve radiologic surveillance challenges. Conduct a comprehensive profiling of the CSF glycoproteome in DGs with the aim of identifying both established and novel CSF biomarkers.
